Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q2 EPS of ($0.19), $0.04 worse than the analyst estimate of ($0.15).

For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.